The FDA has accepted Merck's (NYSE:MRK) supplemental New Drug Application with priority review for its drug Welireg, also known as belzutifan, for the treatment of a rare type of adrenal gland ...
At close: January 17 at 4:12:21 PM GMT+7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback